Stages IIIB-IV Lung Cancer - Non-Small Cell


Many Late Stage Lung Cancer Patients do not Receive Treatment (January 24, 2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from... Continue Reading

Tagrisso®: New Standard of Care for Certain Lung Cancer (December 19, 2016)

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell... Continue Reading

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been... Continue Reading

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (October 25, 2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of... Continue Reading

Patient Panel on Non-Small Cell Lung Cancer Addresses Key Issues (October 14, 2016)

Voices of Value Speak Up: Non-Small Cell Lung Cancer is the first part of a national six-event program presented by Patients Rising and Aimed Alliance. Where is the patient in the national conversation... Continue Reading

FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (September 14, 2016)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Keytruda® (pembrolizumab) for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The... Continue Reading

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer (September 13, 2016)

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors... Continue Reading

Keytruda® Demonstrates Superior Survival Compared to Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer (July 5, 2016)

Teatment with Keytruda® (pembrolizumab) for previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 is superior to standard chemotherapy. Lung cancer... Continue Reading

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference (March 1, 2016)

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged... Continue Reading

Alecensa™ Approved for the Treatment of Recurrent ALK-Positive Lung Cancer (December 24, 2015)

The FDA approved another inhibitor of anaplastic lymphoma kinase (ALK) for treatment of non-small cell lung cancer (NSCLC) today, further expanding precision treatment options. Alecensa™ (Alectinib)... Continue Reading

Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer (November 10, 2015)

Longer follow-up confirms the survival benefit with the use of the PD-1 inhibitor, Opdivo® (nivolumab), compared to the chemotherapy agent, docetaxel, among patients with recurrent non-small cell lung... Continue Reading

Opdivo® Receives Expanded Approval for an Additional Type of Lung Cancer (October 19, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval of Opdivo® (nivolumab) for the treatment of non-squamous, non-small cell lung cancer. Non-small cell lung cancer (NSCLC),... Continue Reading

Iressa® Approved as Initial Therapy for Lung Cancer (September 23, 2015)

The targeted agent Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration (FDA) as initial therapy in the treatment of patients with advanced lung cancer. Specifically, Iressa was... Continue Reading

16th World Conference on Lung Cancer Expected to Highlight Advances in Precision Medicine (September 6, 2015)

Today, September 6, the 16th World Conference on Lung Cancer (WCLC) begins in Denver, Colorado. The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More... Continue Reading

FDA Approves Iressa for Treatment of Patients with Metastatic Non Small Cell Lung Cancer (July 20, 2015)

The U. S. Food and Drug Administration approved IRESSA (gefitinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR)... Continue Reading

Aetna Provides Coverage for Biodesix’ VeriStrat Test (June 25, 2015)

Biodesix, Inc. announced that its VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation (NYSE: AET).  Aetna published a positive coverage policy for the VeriStrat proteomic... Continue Reading

New Targeted Drug Offers Promising Treatment Option in Resistant EGFR-Positive Lung Cancers (June 22, 2015)

Patients with lung cancer driven by a mutation in the EGFR gene frequently respond well to inhibitors that block the mutation’s activity. But eventually, those cancers become resistant to the inhibitor... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS